T-cell targeted therapy tested in type 1 diabetes study

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network (ITN), are published today in The Lancet Diabetes & Endocrinology. The study did not meet its primary endpoint: at 12 months, insulin production, as measured by C-peptide responses, showed no difference in overall decline between the treatment and placebo groups.

Thymoglobulin®, currently licensed for the treatment of organ transplant rejection, is a form of antithymocyte globulin (ATG), a mixture of specialized proteins called antibodies. These antibodies attach themselves to white blood cells known as T cells, interfering with their function and eliminating them temporarily from the bloodstream. During the development of , T cells mistakenly destroy the beta cells of the pancreas, which secrete insulin. ITN investigators hypothesized that treating new-onset type 1 diabetes with thymoglobulin would disrupt T-cell activation and might induce tolerance.

The Phase II START study enrolled 58 new-onset type 1 diabetic patients ages 12 to 35 years old. The patients were randomized 2:1 to receive ATG treatment or placebo. Patients in the ATG group received intravenous infusion of ATG over 4 consecutive days at the start of the study; patients in the placebo group received saline solution. At 6-month intervals, researchers measured of patients in both groups. The study was the first rigorous, placebo-controlled, multicenter study of ATG therapy in patients with new-onset type 1 diabetes.

Further inspection of the ATG treatment group revealed two distinct rates of change during the 12-month period. Most of the decline in beta cell function occurred during the first 6 months. Interestingly, this initial rate of decline in function was limited to younger patients (ages 12 to 21 years old), whereas older patients (above 21 years of age) showed almost no reduction from baseline levels in insulin production over the 12 months. Almost all patients in the treatment group experienced serum sickness and cytokine release syndrome following ATG infusions, and the investigators suggest that this early cytokine induction may have led to the unfavorable loss of beta cell function, particularly in the younger patients.

Analyses of blood samples from START revealed that T cells rapidly decreased following ATG administration, consistent with the known mechanism of action of the drug. However, investigators observed notable differences between two specific T-cell subtypes during the first 6 months: the level of effector memory T cells, important mediators of inflammation, did not decline, while the level of regulatory T cells, which are beneficial in suppressing immune attack, were reduced.

Follow-up of subjects in this trial may yield additional insights into differences in response to ATG, and suggest biomarkers of safety and efficacy to be used in future new-onset type 1 trials. The high-quality clinical specimens collected throughout the study also will be an important resource for uncovering insights about the mechanisms of disease and identifying pathways to target in future studies.

Provided by Immune Tolerance Network

4.7 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

Conditioning regimen beneficial for kidney recipients

Mar 28, 2012

(HealthDay) -- Following a conditioning regimen of lymphoid irradiation (TLI) and antithymocyte globulin (ATG), the majority of HLA-matched kidney and hematopoietic cell transplant recipients can be withdrawn ...

Recommended for you

Economic burden of prediabetes up 74 percent over five years

Nov 20, 2014

The economic burden of diabetes in America continues to climb, exceeding more than $322 billion in excess medical costs and lost productivity in 2012, or more than $1,000 for every American, according to a study being published ...

Gynoid fat resists metabolic risks of obesity

Nov 19, 2014

(HealthDay)—The differences in the developmental profiles of upper-body and lower-body fat depots may explain their opposing associations with obesity-related metabolic disease, according to research published ...

Treating diabetes one meal at a time

Nov 19, 2014

Recent estimates project that as many as one in three American adults will have diabetes in 2050. The American Diabetes Association observes November as American Diabetes Month, and this year's theme is America ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.